MetaCap

Korsana Biosciences Inc. (KRSA)

NASDAQ: KRSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

37.56+2.11 (+5.95%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

KRSA stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$16.14
52-week range
7.19 – 59.36
Day range
34.51 – 39.41
Volume / Avg
265.23K / 119.71K
Beta
—

52-week range

$7.19$59.36

KRSA stock today

Korsana Biosciences (KRSA) closed at $37.56 on Nov 20, up 5.95% (+$2.11), versus the S&P 500's 3.70% decline. Volume was 2.2x the average at 265.23K shares, a sign of unusually heavy trading. Shares are 36.7% below their 52-week high of $59.36, set on Apr 1, 2026 and 422.5% above the 52-week low of $7.19, in the middle of the past year's range.

KRSA is up 322.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 262.5%. Korsana Biosciences has posted a net loss over the last twelve months (EPS of -$16.14), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Korsana Biosciences

Company profile

Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Jonathan Violin M.B.A., Ph.D.
Headquarters
Waltham, MA
Employees
19

Financial highlights

Full financials

In fiscal 2025, Korsana Biosciences generated $2.1 million in revenue, up 3.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Korsana Biosciences reported a net loss of $3.5 million, compared with a loss of $3.1 million a year earlier. Operating margin was -239.8%.

Korsana Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.07M$2.00M$0$297.00K$3.94M
Growth+3.70%—-100.00%-92.47%+71.69%
Net income$-3.53M$-3.06M$-5.26M$-44.08M$-51.65M
EPS (diluted)$-1.11$-1.21$-2.25$-20.28$-1.32

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$44.00+17.15%

  • Strong buy 0
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $70.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-3.19 vs $-0.78
Surprise
-308.97%

KRSA news

All KRSA news

Korsana Biosciences peers

Health Care sector
KRSA peer companies
CompanyPrice% ChgMarket capCompare
SDGRSchrodinger Inc.22.93-12.95%$1.72Bvs KRSA
RAREUltragenyx Pharmaceutical Inc.16.48-4.30%$1.68Bvs KRSA
BRVEBraveheart Bio Inc.20.39+5.81%$1.67Bvs KRSA
TRAXFirst Tracks Biotherapeutics Inc.41.64-6.34%$1.75Bvs KRSA
STOKStoke Therapeutics Inc.26.81-0.45%$1.75Bvs KRSA
ETONEton Pharmaceuticals Inc.60.85-0.83%$1.76Bvs KRSA
AGIOAgios Pharmaceuticals Inc.27.60-4.03%$1.65Bvs KRSA
ZBIOZenas BioPharma Inc.23.85-4.75%$1.62Bvs KRSA

Indexes, lists and sector

Korsana Biosciences stock FAQ

What is Korsana Biosciences's stock price today?

KRSA last traded at $37.56 as of Nov 20, 4:00 PM EST, up 5.95% on the day. Prices are delayed at least 15 minutes.

Does Korsana Biosciences pay a dividend?

No. Korsana Biosciences does not currently pay a regular cash dividend.

Who is Korsana Biosciences's CEO?

Dr. Jonathan Violin M.B.A., Ph.D. is the chief executive officer of Korsana Biosciences Inc., which has about 19 employees.

Has KRSA ever split its stock?

Yes. The most recent KRSA stock split was a 1-for-7 split on Sep 9, 2026, one of 2 splits on record.

What is the KRSA 52-week high?

The 52-week high for KRSA is $59.36 and the 52-week low is $7.19. The stock is currently 36.7% below its high.

Compare KRSA